All News

From Health Lab: Study defines key driver of aggressive ovarian cancer

Story originally posted on Michigan Medicine Health Lab, written by Nicole Fawcett.

Study defines key driver of aggressive ovarian cancer

Researchers created a mouse model to understand how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma and identify potential treatment approaches

A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.

High-grade serous carcinoma, the most common type of ovarian cancer, usually begins in the fallopian tube, before spreading to the ovaries and other pelvic organs

The Path to Discovery

Jennifer Brazil, PhD, Assistant Professor of Pathology at Michigan Medicine began her own research laboratory in 2018. She continued to research the mechanisms by which polymorphonuclear neutrophils (PMN) and epithelial glycans can be targeted to alter neutrophil transepithelial migration and neutrophil function under conditions of intestinal inflammation and repair.

Enhancing Heart Failure Patient Care with the MOS Dashboard

Heart failure with reduced ejection fraction (HFrEF), which measures your heart’s ability to pump oxygen-rich blood out to your body, remains a leading cause of death and hospitalization worldwide. Over the last three decades, clinical trials have highlighted the efficacy of four key medication classes- Beta-blockers, angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).

DiFeo Lab Recognized with Outstanding Journal Article Award

The Molecular and Cancer Therapeutics journal recently awarded Dr. Analisa DiFeo, professor, with their annual Outstanding Journal Article Award for 2025 for her article “Small Molecule Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage Induced Cell Death.”

The Art of Science

Like prisms spread light in a variety of hues, Dr. Yang Xiao’s talents spread across multiple disciplines, creating a spectrum of color in this world. Dr. Xiao is one of Pathology’s newest faculty members and was recruited as a tenure-track assistant professor. However, she is not only a member of Pathology but also holds joint appointments in Biomedical Engineering and Computational Medicine & Bioinformatics departments and is a member of the Bioscience Initiative Single-Cell Spatial Analysis Program (SCSAP).

USCAP's Inaugural Observership Completed at Michigan Medicine's Department of Pathology

The USCAP University Partnership Program (U²P²) is a new opportunity designed to deepen the United States and Canadian Academy of Pathologists (USCAP) investment in international pathologists who have demonstrated excellence, leadership, and a strong commitment to advancing pathology in their home countries.

The Unseen Heroes of Healthcare

Pathology Laboratory Professionals Week is an annual celebration honoring the vital contributions of medical laboratory professionals to patient care and public health. This year, we celebrate from April 21 to 25, 2025.

Kamran Mirza, MD, PhD Receives PAPs Distinguished Service Award

We are pleased to announce that Kamran Mirza, MD, PhD, professor of pathology and assistant chair for pathology education, was awarded the Pakistani-American Pathologists’ Society’s Distinguished Service Award at the United States and Canadian Academy of Pathology.

Dr. Abhijit Parolia - A Rising Scholar

On Thursday, March 20th the National Institutes of Health, National Cancer Institute presented its Rising Scholars Lecture with pathology’s Dr. Abhijit Parolia, assistant professor of experimental pathology, entitled NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.

Using Technology to Advance Patient Care and Safety

In decades past, people often lived lifelong within a narrow geographic region and received healthcare from one institution. Today, our population is highly mobile. Individuals may receive healthcare from locations across the United States and globally. This causes significant safety issues for patients who need blood transfusions, especially those who are unable to relay their medical history.